Discover how new global guidelines aim to combat the rising threat of Candida infections with updated treatments and ...

"Invasive candidiasis is a potentially deadly infection with a mortality rate of around 50%. That's even with the best available treatment," explained the study's lead author Andreas Bäumler.

The new guidelines provide updated diagnostic and therapeutic strategies for both mucocutaneous and invasive candidiasis.

where the infection spreads throughout the body Recurrent yeast infections on the skin Skin Yeast Infection and Invasive Candidiasis If a skin yeast infection is severe and manages to enter the ...

To our knowledge, this report from the International Pediatric Fungal Network is the largest prospective, multicenter observational study dedicated to pediatric and neonatal invasive candidiasis.

Furthermore, SCYNEXIS aims to restart the Phase 3 MARIO study for invasive candidiasis in Q2 2025, pending the FDA lifting a clinical hold. Financially, SCYNEXIS ended 2024 with $75.1 million in ...

The Phase 1 trial of the second-generation triterpenoid antifungal SCY-247, initiated in December of 2024, continues and results are expected in ...

Reason for decision Not eligible for Health Technology Evaluation guidance Further information Decision makers have concluded that this technology will not progress as a potential technology appraisal ...

SCYNEXIS continues to make progress towards the restart of the Phase 3 MARIO study in invasive candidiasis. The Company anticipates the restart, pending the FDA’s lifting of the clinical hold ...